XNCR Jun 2024 25.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 03:20PM EDT
| Previous Close | 2.0300 |
| Open | 0.5000 |
| Bid | 0.1000 |
| Ask | 5.0000 |
| Strike | 25.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.5000 - 0.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 14 |
Business WireXencor Regains CD20 x CD3 Bispecific T-Cell Engager
PASADENA, Calif., June 13, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize
Simply Wall St.Xencor First Quarter 2024 Earnings: Misses Expectations
Xencor ( NASDAQ:XNCR ) First Quarter 2024 Results Key Financial Results Revenue: US$12.8m (down 33% from 1Q 2023). Net...
- GuruFocus.com
Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
Comprehensive Analysis of Financial Performance and Strategic Initiatives
© 2024 Yahoo. All rights reserved.